|

Are Long-Acting TB Injections Available? What WHO’s 2026 Targets Mean

ByLife Choice Note

Short answer: No approved “one-shot cure” for tuberculosis was announced. WHO’s new document is a set of target regimen profiles for developers—not a clinical recommendation, product approval or prescription. It describes the performance a future long-acting injectable (LAI) regimen should aim for: a complete TB preventive course at one injection encounter, or TB disease treatment lasting no more than four months with three or fewer dosing encounters.

  • WHO update: October 28, 2026; technical publication dated October 26
  • Geographic scope: Global research and product-development targets
  • Intended users: Industry, academic and research groups, product-development partners, TB programs, affected communities, civil society and funders
  • What it does not do: Approve a product, replace current oral regimens, or change national treatment guidance

What do “one injection” and “three visits” mean?

The 85-page WHO document separates TB preventive treatment from treatment of TB disease. Its preventive profile aims for an entire course delivered as a single injection at one encounter. For TB disease, it aims for a regimen no longer than four months and delivered in three or fewer dosing encounters.

Those numbers are development targets, not a proven dose schedule. WHO distinguishes a minimum requirement—the threshold at which a candidate remains worth pursuing—from an optimal requirement that is desirable but still intended to be realistic. A headline about “one injection” therefore does not mean patients can replace their current medicines with one shot today.

The target is more than fewer doses

WHO says a useful regimen should be deliverable by a trained health worker at the lowest feasible level of the health system, use a small injection volume, avoid a cold chain, and provide efficacy and safety at least as good as current oral regimens. The profiles also address trial design, total treatment burden, scalability, equitable access, transparent pricing and cost.

This matters because a long-acting formulation could reduce the burden of taking tablets repeatedly over months, but it could also shift work to clinics, injection services and supply systems. Some people may not want an injection or a medicine that remains in the body for a long period. WHO therefore says work on better oral regimens should continue and implementation should preserve patient choice.

What evidence exists—and what is still missing?

WHO reports that several LAI candidates for TB are entering or approaching clinical development. “Candidate” is the key word. The new profile does not present an approved medicine or randomized patient trial showing that a named LAI regimen cures TB, prevents relapse or has an established long-term safety profile.

A separate consensus paper published on October 14, 2026, explains why LAIs are attracting interest in TB and malaria. It also identifies unresolved development issues: translating preclinical results into people, predicting human doses, defining pharmacokinetic and pharmacodynamic requirements, assessing safety and tolerability, and navigating regulation. The paper reflects a multidisciplinary workshop; it is not a clinical-effectiveness trial. Its disclosures also note that several contributors work for organizations or companies involved in drug development.

Does this change care in South Korea or elsewhere today?

Not by itself. A WHO target profile does not create marketing authorization, reimbursement or supply in any country. Each candidate would still need clinical evidence and review by the relevant regulator, followed by decisions about national guidance and delivery. People currently receiving TB preventive treatment or treatment for TB disease should not stop medicines or delay follow-up while waiting for a future injection. Drug resistance, coexisting conditions and adverse effects require individualized clinical assessment.

Important limits

  • This is an R&D consensus framework, not a trial proving clinical benefit.
  • One injection and three or fewer encounters are targets, not approved label instructions.
  • The document cannot establish which candidate will succeed, when one may become available, or what it will cost.
  • It is global guidance for developers and does not automatically change approval or treatment policy in South Korea, the United States or any other country.

Primary sources

By: Life Choice Note — an independent personal health-information explainer based on official and primary sources.
Reviewed: October 29, 2026
Note: This article provides general information and does not diagnose TB or direct anyone to start, stop or replace treatment. Discuss individual decisions with a qualified clinician.

Related guides